Clinical trials: Recurrent Epithelial Ovarian Cancer
Ovarian Cancer, Neoplasms
Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer
The purpose is to assess the efficacy and toxicity of the study agent, enzastaurin, in participants with recurrent or persistent ovarian cancer.
- Conditions
- Ovarian Cancer, Neoplasms, Carcinoma
- Trial name
- NCT00420381
- Testing
- enzastaurin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma
EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
This phase I trial studies the side effects and the best dose of giving EGEN-001 together with pegylated liposomal doxorubicin hydrochloride in treating patients with ovarian epithelial, fallopian tube, or primary peritoneal…
- Conditions
- Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma
- Trial name
- NCT01489371
- Testing
- Laboratory Biomarker Analysis, PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1, Pegylated Liposomal Doxorubicin Hydrochloride
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Fallopian Tubes Cancer
Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
The purpose of this study is to see if the investigators can improve the treatment of this type of cancer. They want to find out what effects, good and/or bad, giving heated chemotherapy into the belly, known as hyperthermic…
- Conditions
- Ovarian Cancer, Fallopian Tubes Cancer, Peritoneal Cancer
- Trial name
- NCT01767675
- Testing
- Secondary Cytoreductive Surgery, Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC), platinum-based systemic chemotherapy postoperatively
- Where
- 11 sites in United States
- Volunteers
- 99 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Epithelial Ovarian Cancer
Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer
Single -arm, multicenter phase-II trial for catumaxomab and chemotherapy in patients with recurrent ovarian cancer to investigate the feasibility and clinical activity of initial intraperitoneal catumaxomab followed by…
- Trial name
- NCT01815528
- Testing
- Catumaxomab
- Where
- Germany
- Volunteers
- 2 people
- Sponsor
- JSehouli
Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor
Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor
This study is phase II, open label, clinical trial to determine the efficacy of Niraparib re-treatment with Bevacizumab of assessment progression-free survival(6 months PFS rate) with platinum-sensitive recurrent ovarian cancer…
- Trial name
- NIRVANA-R (NCT04734665)
- Testing
- Niraparib-Bevacizumab
- Where
- South Korea
- Volunteers
- 44 people
- Sponsor
- Yonsei University
Ovarian Cancer
Methotrexate Plus Dipyridamole in Treating Patients With Advanced Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Dipyridamole may increase the effectiveness of methotrexate and kill more tumor cells.
- Trial name
- NCT00002487
- Testing
- dipyridamole, methotrexate
- Where
- 2 sites in Canada
- Sponsor
- Ottawa Regional Cancer Centre
Recurrent Platinum-resistant Ovarian Cancer
Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer
This study is intend to improve the progression-free survial of the recurrent paltinum-resistant ovarian cancer. All the participants will receive camrelizumab combined with apatinib.
- Trial name
- NCT04068974
- Testing
- Camrelizumab (SHR-1210), Apatinib
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Peking Union Medical College Hospital
Epithelial Ovarian Carcinoma
Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma
The purpose of this study is to determine whether DCVAC/OvCa added to chemotherapy may result in prolongation of Overall Survival (OS).
- Trial name
- NCT02107378
- Testing
- DCVAC/OvCa, Standard of Care (Paclitaxel or topotecan or doxorubicin)
- Where
- 12 sites in Czechia, Germany and 1 more
- Volunteers
- 22 people
- Sponsor
- SOTIO a.s.
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer.
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor
- Trial name
- NCT00087191
- Testing
- EF5, motexafin lutetium, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Ovarian Cancer
Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer
This study aims to investigate the effect of involved-field radiotherapy for recurrent ovarian cancer after primary standard treatment.
- Trial name
- NCT03618706
- Testing
- Involved-field radiotherapy
- Where
- South Korea
- Volunteers
- 107 people
- Sponsor
- Yonsei University
Ovarian Cancer
Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer
The study was designed to evaluate the efficacy and safety of apatinib with albumin-bound paclitaxel in patients with platinum-resistant recurrent ovarian cancer.
- Trial name
- NCT03942068
- Testing
- albumin-bound paclitaxel, Apatinib
- Volunteers
- 35 people
- Sponsor
- Henan Cancer Hospital
Ovarian Cancer, Fallopian Tube Cancer
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
HS-20089 is an investigational antibody-drug conjugate (ADC) composed of a humanized IgG1 anti-B7-H4 monoclonal antibody conjugated to the topoisomerase I inhibitor payload via a protease-cleavable linker, with an average…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
- Trial name
- NCT06014190
- Testing
- HS-20089
- Where
- 28 sites in China
- Volunteers
- 460 people
- Sponsor
- Hansoh BioMedical R&D Company
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients with recurrent…
- Trial name
- NCT00003523
- Testing
- aminocamptothecin colloidal dispersion
- Where
- 65 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Fallopian Tube Cancer, Ovarian Cancer
Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00003380
- Testing
- etoposide, pegylated liposomal doxorubicin hydrochloride
- Where
- 63 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- NEXUS-01 (NCT06465069)
- Testing
- LY4052031, Pembrolizumab
- Where
- 39 sites in United States, Australia and 6 more
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer
A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer) is a Phase 3 study during which patients with recurrent or persistent low-grade serous (LGS) carcinomas of the ovary, fallopian tube or primary peritoneum will…
- Conditions
- Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Peritoneal Cancer
- Trial name
- NCT01849874
- Testing
- MEK162, MEK inhibitor; oral, Physician's choice chemotherapy
- Where
- 226 sites in United States, Australia and 17 more
- Volunteers
- 341 people
- Sponsor
- Pfizer
Platinum-resistant Recurrent Ovarian Cancer, Advanced Solid Tumor
APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
An open, multicenter, dose-exploring Phase I trial include Part A and Part B to evaluate the safety, tolerability and efficacy of APG-2449.
- Trial name
- NCT06687070
- Testing
- APG -2449, PLD
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Ascentage Pharma Group Inc.
Ovarian Cancer, Primary Peritoneal Cancer
Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer
The purpose of this study is to evaluate the objective response rate and safety in platinum-resistant epithelial ovarian/fallopian tube/primary peritoneal cancer patients treated with vinorelbine and gemcitabine combination…
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT01196559
- Testing
- Vinorelbine and Gemcitabine
- Where
- 4 sites in South Korea
- Volunteers
- 44 people
- Sponsor
- The Catholic University of Korea
Recurrent Ovarian Cancer
The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab
The study will be a Prospective, Single-arm, Phase Ⅱ Clinical Study. This study intends to explore the efficacy and safety of Fuzuloparib combined with bevacizumab in the maintenance treatment of patients with platinum-sensitive…
- Trial name
- NCT05819060
- Testing
- Fuzuloparib Combination with Bevacizumab
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Fudan University
Platinum-resistant Ovarian Cancer, Testicular Cancer
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with…
- Conditions
- Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer
- Trial name
- NCT06515613
- Testing
- CTIM-76
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 156 people
- Sponsor
- Context Therapeutics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.